Sunday August 20th 2017

Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

Abstract: Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4+ T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some variability among patients. Further studies may confirm if slower reduction of circulating Th17 cells following fingolimod initiation predisposes to relapses. (Source: Journal of Neuroimmunology)

Visit link – 

Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

U.S. House Democrats Launch Probe Into MS Drug Pricing U.S. House Democrats Launch Probe Into MS Drug Pricing
U.S. House Democrats Launch Probe Into MS Drug Pricing U.S. House Democrats Launch Probe Into MS Drug Pricing

U.S. House Democrats said on Thursday they were launching an investigation into why prices for multiple sclerosis (MS) [Read More]

MassDevice.com +5 | The top 5 medtech stories for August 18, 2017
MassDevice.com +5 | The top 5 medtech stories for August 18, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]